

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS: Collins et al.  
SERIAL NUMBER: 09/868,123 EXAMINER : Regina M. Deberry  
FILING DATE: April 2, 2002 ART UNIT : 1647  
FOR: CYTOKINE RECEPTOR CHAIN

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Applicants make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are enclosed.


This Information Disclosure Statement is being filed after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311. The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 22058-514 NATL.

08/24/2006 SSITHIB1 00000111 09868123


01 FC:1806

180.00 Op

Respectfully submitted,

  
David E. Johnson, Reg. No. 46,874  
Attorney(s) for Applicants  
MINTZ, LEVIN, COHN, FERRIS,  
GLOVSKY and POPEO, P.C.  
Address all written correspondence to  
**Customer no.: 30623**  
Tel: (617) 542-6000  
Fax: (617) 542-2241

Date: August 22, 2006



Express Mail No.: EV 869858665 US  
Date of Deposit: August 22, 2006

Page 1 of 1  
Attorney Docket No.: 22058-514 NATL

Please type a plus sign (+) in this box



Modified Form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<b>Application Number</b>	09/868,123
<b>Filing Date</b>	April 2, 2002
<b>First Named Inventor</b>	Collins
<b>Group Art Unit</b>	1647
<b>Examiner Name</b>	Regina M. Deberry
<b>Attorney Docket Number</b>	22058-514 NATL

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
------------------	-------------	-----------------------------	------------	-------------------------------------	-------	--------------	-------------------------------

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C20	Bost et al. <i>Immunology</i> , 87:633-641 (1996)
	C21	Grünig et al. <i>Science</i> , 282:2261-2263 (1998)
	C22	Van Der Pouw Kraan et al. <i>Clin. Exp. Immunol.</i> , 111:129-135 (1998)

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

COPY

Please type a plus sign (+) in this box



PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/868,123
	<b>Filing Date of U.S. Natl Appl.</b>	06/13/01
	<b>First Named Inventor</b>	Collins
	<b>Group Art Unit</b>	Not Yet Assigned
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,696,234	12/09/97	Zurawski et al.			
	A2	5,599,905	02/04/97	Mosley et al.			
	A3	5,710,023	01/20/98	Collins et al.			

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 97/15663	Amrad Operations Pty. Ltd.	05/01/1997	
	B2	WO 94/04680	Schering Corporation	03/03/1194	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Obiri et al. (1995). "Receptor for Interleukin 13" <i>J. Biol. Chem.</i> <u>270</u> (15): 8797-8804.
	C2	Vita et al. (1995). "Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types" <i>J. Biol. Chem.</i> <u>270</u> (8): 3512-3517.
	C3	Zurawski et al. (1995). "The Primary Binding subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor" <i>J. Biol. Chem.</i> <u>270</u> (23): 13869-13878.
	C4	International Search Report for PCT/US99/29493. Mailed on April 25, 2000.
	C5	Written Opinion for PCT/US99/29493. Mailed on January 26, 2001.
	C6	McKenzie et al. (1993). "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function" <i>Proc. Natl. Acad. Sci. USA</i> <u>90</u> : 3735-3739
	C7	Minty et al. (1993). "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses" <i>Nature</i> <u>362</u> : 248-250
	C8	Punnonen et al. (1994). "IL-13 Induces Proliferation, Ig Isotype Switching, and Ig Synthesis by Immature Human Fetal B Cells" <i>J. Immunol.</i> <u>152</u> : 1094-1102
	C9	Punnonen et al. (1993). "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells" <i>Proc. Natl. Acad. Sci. USA</i> <u>90</u> : 3730-3734
	C10	Cocks et al. (1993). "IL-13 Induces Proliferation and Differentiation of Human B Cells Activated by the CD40 Ligand" <i>Int. Immunol.</i> <u>5</u> (6): 657-663.
	C11	Zurawski et al. (1993). "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction" <i>EMBO J.</i> <u>12</u> : 2663-2670
	C12	Hilton et al. (1996). "Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor" <i>Proc. Natl. Acad. Sci. USA</i> <u>93</u> : 497-501.
	C13	Shanafelt et al. (1998). "An immune cell-selective interleukin 4 agonist" <i>Proc. Natl. Acad. Sci. USA</i> <u>95</u> : 9454-9458.

Date of Deposit: May 9, 2002

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
C14		Aversa et al. (1993). "An Interleukin 4 Mutant Protein Inhibits both IL-4 or IL-13 induced Human Immunoglobulin G4 and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors" <i>J. Exp. Med.</i> <u>178</u> : 2213-2218.
C15		Grunewald et al. (1998). "An Antagonistic IL-4 Mutant Prevents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor system Completely Abrogates Humoral Immune Response to Allergen and Development of Allergic Symptoms In Vivo" <i>J. Immunol.</i> <u>160</u> : 4004-4009.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

**COPY**

Please type a plus sign (+) in this box



Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	09/868,123
	<b>Filing Date</b>	04/02/02
	<b>First Named Inventor</b>	Collins
	<b>Group Art Unit</b>	1647
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	22058-514 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication mm/dd/yyyy	Translation Yes No	
	B3	WO	97/31946	Genetics Institute, Inc.	09/04/97		
	B4	WO	97/33913	Zymogenetics, Inc.	09/18/97		
	B5	WO	97/47741	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/18/97		
	B6	WO	97/47742	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/18/97		
	B7	WO	98/10638	Amrad Operations Pty. Ltd.	03/19/98		
	B8	EP	0 812 913	Smithkline Beecham Corporation; and Human Genome Sciences, Inc.	12/17/97		
	B9	FR	2 742 156	Sanofi Societe Anonyme	06/13/97		X

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C16	Caput, et al. (1996). "Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor $\alpha$ Chain" J Biol Chem 271: 16921-16926.
	C17	Donaldson, et al. (1998). "The Murine IL-13 Receptor $\alpha 2$ : Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor $\alpha 1$ " J Immun 161: 2317-2324.
	C18	Collins, et al. (1991). "Comparison of two distinct ligand binding chains for the IL13 receptor in the mouse" J Allergy Clin Immun 99: 287. <b>(ABSTRACT ONLY)</b>
	C19	Supplementary Partial European Search Report, for EP 99966166.3-2401-US9929493 dated May 13, 2002.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.